RE:A few Questions for the board.....
InvestorRights wrote: What is the best case scenario for this company to start earning some revenue? What is the burn rate for the 9 Million dollars that is left? How many years or months will that last without further dilution? Whi is selling at these levels? and why are they selling at such a low share price?
I'll keep it brief ; )...We certainly don't need US participation to get to that magic number of 20-25 patients...we're already about half way there. Importantly, "58%" of the first 12 treated had "qualified" for a second treatment (despite the under treatment in "all" patients). So I believe this under treated cohort will ultimately not necessitate durable response (1 year CR) data on additional patients. There "should" also be a big enough patient pool across "4 sites" in Canada (with 5th site pending) to enroll/treat another 12 by year end (1 patient monthly). Furthermore, the impact of Covid in Canada has been substantially mitigated & we now have optimized trial/Covid protocols in place. It's therefore not an unreasonable expectation that we could get 12 more patients treated by year end for under $1 million (conservatively) in Canada alone. If they can meet this conservative threshold, they could get CR data readouts on this additional cohort by April 2021, & then hopefully get a BTD before June.
As for the US, TLT would not onboard more than they can financially afford... & 5 "potential" sites could mean fewer. The key will be getting to approval/commercialization based on 1 yr data from 20+ patients imo with money to spare. With a BTD, warrant exercise & strong science in hand, this should be readily achievable in 2022. Beyond that (or even before), we can further explore licensing deals/partnerships to carry our technology forward. If we decide to stay independent, shareholders should at least be relieved that any additional funding should gratefully be done at a shareholder-friendly pps. All JMO.